Valley National Advisers Inc. Has $255,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Valley National Advisers Inc. boosted its position in Edwards Lifesciences Co. (NYSE:EW) by 6.0% in the 1st quarter, HoldingsChannel reports. The firm owned 2,677 shares of the medical research company’s stock after acquiring an additional 152 shares during the period. Valley National Advisers Inc.’s holdings in Edwards Lifesciences were worth $255,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Trust Co. of Oklahoma acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $298,000. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Edwards Lifesciences by 0.4% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,609,866 shares of the medical research company’s stock worth $153,839,000 after acquiring an additional 6,563 shares during the last quarter. Plimoth Trust Co. LLC lifted its position in Edwards Lifesciences by 5.4% during the first quarter. Plimoth Trust Co. LLC now owns 3,834 shares of the medical research company’s stock worth $366,000 after acquiring an additional 195 shares during the last quarter. Buffington Mohr McNeal lifted its position in Edwards Lifesciences by 6.3% during the first quarter. Buffington Mohr McNeal now owns 6,700 shares of the medical research company’s stock worth $640,000 after acquiring an additional 400 shares during the last quarter. Finally, Cullinan Associates Inc. lifted its position in Edwards Lifesciences by 8.6% during the first quarter. Cullinan Associates Inc. now owns 13,911 shares of the medical research company’s stock worth $1,329,000 after acquiring an additional 1,100 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Evercore ISI raised their price objective on shares of Edwards Lifesciences from $89.00 to $91.00 and gave the stock an “in-line” rating in a research report on Tuesday. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Mizuho raised their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Oppenheimer raised their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Finally, StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday, June 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $95.18.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded down $0.14 during midday trading on Wednesday, reaching $91.09. 1,497,118 shares of the company were exchanged, compared to its average volume of 3,443,672. The stock’s 50-day moving average price is $87.99 and its 200-day moving average price is $85.56. The stock has a market cap of $54.89 billion, a P/E ratio of 39.26, a PEG ratio of 3.38 and a beta of 1.11. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total transaction of $437,700.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $4,108,777.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the transaction, the director now owns 4,486 shares in the company, valued at $414,596.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $4,108,777.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 119,849 shares of company stock valued at $10,579,038. 1.27% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.